Interview: Ellson Chen, President & CEO, Vita Genomics, Taiwan
The President & CEO of Vita Genomics talks about the advantages that genomic testing offer both to sick and healthy patients, as well as the opportunities to catalogue the science…
Address: 7 Fl., No. 6, Sec. 1, Jung-Shing Road, Wugu Shiang, Taipei, Taiwan
Tel: (+886) 2-8976-9123
Web: http://www.vitagenomics.com/
Vita Genomics, founded in March 2001, has established its headquarter in Taiwan, a marketing office in California, USA, and a wholly owned subsidiary GeneCore in Shanghai, China. Vita Genomics has envisioned itself to be an important player in the healthcare industry by offering advanced and targeted molecular diagnostic products and services, providing more efficient and safer medical solutions, improving the drug development process, and lowering the overall healthcare cost through the pharmacogenomics approaches.Vita Genomics has already built up strong relationships with research institutions and medical organizations throughout Taiwan and China. We are constantly looking for pharmaceutical partners who can benefit from identifying patients for drug responsiveness prior to treatments, partners who would fund expanded pharmacogenomics studies that will enable us to validate the responsiveness of all significant genotypes, and partners who would co-develop DNA-based molecular diagnostic products. Vita Genomics is an active participant in modernizing Taiwan healthcare system. We are establishing the infrastructure needed to add the molecular profile information to the healthcare integrated circuit (IC) card. This is a first step in creating personalized medicine in the future. In addition, Vita Genomics can act as the conduit between the western world and China because we have already established a beachhead in Shanghai.
Vita Genomics follows the high standards of US FDA guidelines in collecting samples in conducting research and clinical studies.Vita Genomics concentrates on the elucidation of the genes and pathways involved in various diseases and on the drug responsiveness of patients in an attempt to improve the healthcare system.
The President & CEO of Vita Genomics talks about the advantages that genomic testing offer both to sick and healthy patients, as well as the opportunities to catalogue the science…
Unlike many multinational CROs, PAREXEL decided to base its Asia Pacific operations in Taipei instead of Singapore. To what extent was this decision a result of Taiwan’s business environment and…
Could you please give our readers an overview of the importance of Taiwan for Celgene in a regional and a global context? What is attractive in Taiwan for Celgene? Celgene…
Novo Nordisk is one of the few pharmaceutical multinationals focused in one key therapeutic area. Perhaps you could start by telling our readers about how diabetes has evolved in Taiwan…
Please tell our readers about the importance of GSK Taiwan within the context of the company’s global operations, and also what there is in Taiwan that makes it so attractive…
Medigen was created in 1999 and is a listed company. How did the vision for the company come about, and what was it that attracted today’s main shareholders to Medigen?…
Genovate was founded in 1995. It is a very interesting story: a mix of biotech, the history with American company Genelabs, government investments and also private investment through Chinachem. Can…
Please describe the activities of the IRPMA to our readers, and explain the membership advantages of your association. Today the IRPMA consists of 37 multinational research-based pharmaceutical manufacturers, as well…
The Development Centre for Biotechnology was founded in 1984 as a tool for connecting biotechnological academia to the Taiwanese industry and promoting the strengths of Taiwan’s biopharmaceutical sector to the…
Please explain the factors that led to the creation of the Taiwan Intellectual Property Office, and its main activities today. For the Taiwanese government, intellectual property (IP) rights are very…
See our Cookie Privacy Policy Here
